By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Pierre Fabre 

Centre d'Immunologie Pierre FABRE
5, avenue Napolean III - BP 497
St. Julien en Genevois Cedex    74164  France
Phone: 33-4-50-35-35-55 Fax: 33-4-50-35-35-90




Merck & Co.  Cancer

Company News
Pierre Fabre Release: EMA To Start The Review Of The Marketing Authorization Applications For Encorafenib And Binimetinib For The Treatment Of BRAF-Mutant Advanced Melanoma 8/28/2017 7:51:44 AM
Noventure And Pierre Fabre Enter Into An Agreement To Commercialise Aprotecol In Italy 7/18/2017 9:06:16 AM
Pierre Fabre Acquires Promising Assets From Igenica, Inc. In The Field Of Immuno-Oncology 5/24/2017 8:06:18 AM
Pierre Fabre Publishes New Data On Dosing Errors With Generic Propranolol For The Treatment Of Infantile Hemangiomas 4/24/2017 6:23:30 AM
Pierre Fabre And H-Immune Announce Strategic Research Partnership To Develop Potentially Ground-Breaking Cancer Immunotherapies 3/21/2017 6:51:58 AM
Pierre Fabre And Hill Dermaceuticals Announce A Strategic Commercial Partnership For TOLAK (Fluorouracil) Cream 4% In The USA And Beyond 3/6/2017 10:46:36 AM
PIQUR Release: Pharma And Pierre Fabre Announce Partnership In Dermato-Oncology 1/11/2017 10:06:29 AM
Pierre Fabre And Array BioPharma (ARRY) Release: COLUMBUS Phase 3 Study Results In BRAF-Mutant Melanoma Presented At Society For Melanoma Research Annual Congress 11/9/2016 10:27:43 AM
Array BioPharma (ARRY), Pierre Fabre And Merck KGaA (MKGAF.PK), Darmstadt, Germany Announce Phase 3 BEACON CRC Trial 6/6/2016 10:58:54 AM
Merck & Co. (MRK) Partners With Array BioPharma (ARRY) And Pierre Fabre To Initiate BRAF-Mutant CRC Phase III Trial 6/6/2016 9:59:43 AM